SuviCa

Executive Summary

SuviCa, Inc. is a private biotechnology company headquartered in San Diego, California, founded in 2010. The company is dedicated to discovering and developing novel small molecule therapeutics for cancer treatment. Its innovative approach targets an under-exploited cellular mechanism that is critical for cancer regrowth following standard therapies such as chemotherapy and radiation. By focusing on this mechanism, SuviCa aims to address a key gap in current cancer care—preventing relapse and improving long-term outcomes for patients. The company operates at the preclinical stage, leveraging its proprietary platform to advance a pipeline of candidate drugs toward clinical development. Despite being private and not yet having disclosed specific financial data or a funded pipeline, SuviCa's scientific focus on a differentiated target positions it uniquely in the oncology landscape. The company's research emphasis on cancer re-growth suggests potential applicability across multiple tumor types, offering a broad therapeutic opportunity if successful. However, as a preclinical entity, SuviCa faces significant development risks, including the need for robust efficacy and safety data to advance toward the clinic and attract potential partnerships or financing.

Upcoming Catalysts (preview)

• Q2 2027IND-enabling studies completion35% success
• Q4 2026Series A financing round50% success
• Q3 2026Lead candidate selection and preclinical proof-of-concept data60% success